推荐产品
表单
powder
包装
pkg of 1 × 1 g ((890890P-1G))
pkg of 2 × 100 mg ((890890P-200MG))
pkg of 5 × 100 mg ((890890P-100MG))
pkg of 1 × 25 mg ((890890P-25MG))
制造商/商品名称
Avanti Research™ - A Croda Brand
应用
advanced drug delivery
脂质类型
transfection
cationic lipids
运输
dry ice
储存温度
−20°C
SMILES字符串
[H]C(C[N+](C)(C)C)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O.[Cl-]
InChI
1S/C42H80NO4.ClH/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-41(44)46-39-40(38-43(3,4)5)47-42(45)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2;/h20-23,40H,6-19,24-39H2,1-5H3;1H/q+1;/p-1/b22-20-,23-21-;
InChI key
KSXTUUUQYQYKCR-LQDDAWAPSA-M
应用
18:1 TAP (DOTAP)可用于在氯仿溶液中形成干膜，制备阳离子脂质体。也用于标准储备溶液中，制备阳离子脂质体。
生化/生理作用
DOTAP（1,2-二油酰基-3-三甲基铵-丙烷）为阳离子脂质结构，用于体内和体外核酸和蛋白递送。脂质组成和细胞类型会影响 DOTAP 的转染潜能。DOTAP介导造血干细胞(HSCs)的基因敲低技术。
包装
5 mL透明玻璃密封安瓿瓶(890890P-200mg)
5 mL透明玻璃密封安瓿瓶(890890P-25mg)
5 mL透明玻璃密封安瓿瓶(890890P-500mg)
60 mL琥珀色宽口螺帽玻璃瓶(890890P-1g)
法律信息
Avanti Research is a trademark of Avanti Polar Lipids, LLC
通常也和此产品一起购买
产品编号
说明
价格
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Cationic liposomes induce cytotoxicity in HepG2 via regulation of lipid metabolism based on whole-transcriptome sequencing analysis
Li Y, et al.
BMC Pharmacology & Toxicology, 19(1), 43-43 (2018)
Efficient siRNA delivery by the cationic liposome DOTAP in human hematopoietic stem cells differentiating into dendritic cells
Martino S, et al.
BioMed Research International, 2009 (2009)
Analysis of cationic liposomes by reversed-phase HPLC with evaporative light-scattering detection
Zhong Z, et al.
Journal of Pharmaceutical and Biomedical Analysis, 51(4), 947-951 (2010)
Hojun Kim et al.
ACS nano, 12(9), 9196-9205 (2018-08-08)
The success of gene technologies hinges on our ability to engineer superior encapsulation and delivery vectors. Cubosomes are lipid-based nanoparticles where membranes, instead of enveloping into classic liposomes, intertwine into complex arrays of pores well-ordered in a cubic lattice. These
Elias J Sayour et al.
Nano letters, 18(10), 6195-6206 (2018-09-28)
Translation of nanoparticles (NPs) into human clinical trials for patients with refractory cancers has lagged due to unknown biologic reactivities of novel NP designs. To overcome these limitations, simple well-characterized mRNA lipid-NPs have been developed as cancer immunotherapeutic vaccines. While
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门